Clinical Trials | October 27, 2021
Dr Lal PathLabs to acquire Suburban Diagnostics for Rs 925 crore
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
_256_384.png)
MTL, with over 40 years of experience in packaging, caters to the requirements of the FMCG, F&B, homecare, personal care, agrochemicals, pharmaceutical, and liquor industries
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
PEL will explore the PLI scheme and apply if its beneficial.
Subscribe To Our Newsletter & Stay Updated
